Rundu Medical released its 2026 interim report on August 27. First-half operating revenue was 3.194 billion yuan, down 8.0% year on year. Net loss attributable to the parent company was 87.87 million yuan, narrowing from a loss of 121 million yuan in the same period last year. Net loss attributable to the parent company after deducting non-recurring items was 80.67 million yuan, compared with a loss of 134 million yuan a year earlier. Net operating cash flow was 273 million yuan, up 77.7% year on year. Second-quarter revenue was 1.68 billion yuan, down 6.9% year on year, and net loss attributable to the parent company was 34.31 million yuan, narrowing from a loss of 51.39 million yuan in the same period last year. The company said that under the impact of policies such as domestic centralized procurement price cuts and package unbundling, product sales volume and hospital-end prices fell, leading to lower revenue, but the loss narrowed through optimizing the business structure and controlling the expense ratio. In the industrial segment, overseas market expansion for the glycated series products was strong, with revenue up 26.18% year on year.
Shanghai Runda Med Tech CoDomestic centralized procurement price cuts and package unbundling reduced revenue.
